Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4729505 | 0.88 | TAAR1 (0.54) | TAAR1TSHRPTGS1PTGS2ADRA2A | |
| Ammonia Solution, Strong SCHEMBL28852825 | 0.86 | TAAR1 (0.52) | TAAR1TSHRPTGS1PTGS2ADRA2A | |
| SCHEMBL4385612 | 0.85 | TAAR1 (0.48) | TAAR1TSHRPTGS1PTGS2ADRA2A | |
| SCHEMBL10341070 | 0.85 | TAAR1 (0.52) | TAAR1TSHRPTGS1PTGS2ADRA2A | |
| SCHEMBL10667983 | 0.85 | TAAR1 (0.57) | TAAR1TSHRPTGS1PTGS2ADRA2A | |
| Hydrochloric Acid SCHEMBL7533264 | 0.83 | TAAR1 (0.55) | TAAR1TSHRPTGS1PTGS2ADRA2A | |
| SCHEMBL13667320 | 0.83 | TAAR1 (0.50) | TAAR1TSHRPTGS1PTGS2ADRA2A | |
| SCHEMBL20146704 | 0.80 | TAAR1 (0.73) | TAAR1TSHRPTGS1PTGS2ADRA2A | |
| SCHEMBL20135772 | 0.80 | TAAR1 (0.73) | TAAR1TSHRPTGS1PTGS2ADRA2A | |
| SCHEMBL30963576 | 0.80 | TAAR1 (0.55) | TAAR1TSHRPTGS1PTGS2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796696-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9765065-B2 | Therapeutic substituted cyclopentanes | ALLERGAN, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9765065-B2 | Therapeutic substituted cyclopentanes | ALLERGAN, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170144999-A1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES | ALLERGAN, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170144999-A1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES | ALLERGAN, INC. | 2017-05-25 | — | — | US | disclosed |
| US-9591935-B2 | Therapeutic substituted cyclopentanes | ALLERGEN, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9591935-B2 | Therapeutic substituted cyclopentanes | ALLERGEN, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20170057941-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. | 2017-03-02 | — | — | US | disclosed |
| US-9365485-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150274658-A1 | THERAPEUTIC LACTAMS | ALLERGAN, INC. (US) | 2015-10-01 | — | — | US | disclosed |
| US-20080119539-A1 | THERAPEUTIC AMIDES | ALLERGAN, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080086013-A1 | CARBOMETALLATION OF ALKYNES AND IMPROVED SYNTHESIS OF UNIQUINONES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-04-10 | — | — | US | disclosed |
| US-20080058387-A1 | 5-(3-(3-(4-(1-hydroxyhexyl)phenyl)-4-oxo-thiazolidin-2-yl)propyl)thiophene-2-carboxylic acid; prostaglandin agonist; ocular hypotensive agents; post-surgical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts | ALLERGAN, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080058397-A1 | 5-(3-(3-(4-hexanoylphenyl)-2,5-dioxoimidazolidin-4-yl)propyl)thiophene-2-carboxylic acid; prostaglandin agonist; ocular hypotensive agent; post-sergical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts | OLD DAVID W | 2008-03-06 | — | — | US | disclosed |
| US-20080051374-A1 | Therapeutic Amides and related Compounds | ALLERGAN, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080045576-A1 | THERAPEUTIC N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES | ALLERGAN, INC. | 2008-02-21 | — | — | US | disclosed |
| US-20080039505-A1 | THERAPEUTIC LACTAMS | ALLERGAN, INC. | 2008-02-14 | — | — | US | disclosed |
| WO-2008019196-A2 | CARBOMETALLATION OF ALKYNES AND IMPROVED SYNTHSIS OF UBIQUINONES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-02-14 | — | — | WO | disclosed |
| EP-0652863-A1 | NON-PEPTIDIC SURROGATES OF THE LDV SEQUENCE AND THEIR USE IN THE TREATMENT OF INFLAMMATION, AUTOIMMUNE DISEASES AND TUMOUR PROGRESSION | YEDA RESEARCH AND DEVELOPMENT COMPANY, LTD. (IL) | 1995-05-17 | — | — | EP | disclosed |
| WO-1994002445-A1 | NON-PEPTIDIC SURROGATES OF THE LDV SEQUENCE AND THEIR USE IN THE TREATMENT OF INFLAMMATION, AUTOIMMUNE DISEASES AND TUMOUR PROGRESSION | YEDA RESEARCH AND DEVELOPMENT CO. LTD. AT THE WEIZMANN INSTITUTE OF SCIENCE (IL) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080086013-A1 | CARBOMETALLATION OF ALKYNES AND IMPROVED SYNTHESIS OF UNIQUINONES | NDUFA10, NDUFB10, NDUFV1 | TAAR1 3174/4885TSHR 4878/4885PTGS1 1339/4885 |
| US-20080051374-A1 | Therapeutic Amides and related Compounds | GOT2, ACER2, GOT1 | TAAR1 3249/4885TSHR 2257/4885PTGS1 376/4885 |
| US-20150274658-A1 | THERAPEUTIC LACTAMS | CLPP, NOTUM, PEPD | TAAR1 4882/4885TSHR 4505/4885PTGS1 1111/4885 |
| US-20080119539-A1 | THERAPEUTIC AMIDES | GOT2, GOT1, ARG2 | TAAR1 3010/4885TSHR 2420/4885PTGS1 331/4885 |
| US-20080039505-A1 | THERAPEUTIC LACTAMS | CLPP, NOTUM, PEPD | TAAR1 4882/4885TSHR 4505/4885PTGS1 1111/4885 |
| US-20080045576-A1 | THERAPEUTIC N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES | GOT2, GOT1, NME4 | TAAR1 3246/4885TSHR 1819/4885PTGS1 313/4885 |
| US-20080058397-A1 | 5-(3-(3-(4-hexanoylphenyl)-2,5-dioxoimidazolidin-4-yl)propyl)thiophene-2-carboxylic acid; prostaglandin agonist; ocular hypotensive agent; post-sergical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts | PTGIS, PTGIR, PTGS1 | TAAR1 1668/4885TSHR 562/4885PTGS1 3/4885 |
| US-20080058387-A1 | 5-(3-(3-(4-(1-hydroxyhexyl)phenyl)-4-oxo-thiazolidin-2-yl)propyl)thiophene-2-carboxylic acid; prostaglandin agonist; ocular hypotensive agents; post-surgical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts | PTGIS, PTGIR, PTGS1 | TAAR1 1282/4885TSHR 387/4885PTGS1 3/4885 |
| US-20170057941-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ABCB1, THPO, UGT2B7 | TAAR1 4425/4885TSHR 2567/4885PTGS1 857/4885 |
| US-20170144999-A1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES | CYP11B2, CYP11B1, HMGCR | TAAR1 416/4885TSHR 893/4885PTGS1 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.